Mona Parikh, MD
Family Medicine · Newark, DENPI 1639141328
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.3% of the total across 172 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations.
Across 172 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$556
- Boehringer Ingelheim$502
- Lilly USA, LLC$467
- AbbVie$235
- Exact Sciences$234
- Astellas Pharma US Inc$224
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,24595%
- Education$1595%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 32 | $556 |
| Boehringer Ingelheim | 17 | $502 |
| Lilly USA, LLC | 26 | $467 |
| AbbVie | 11 | $235 |
| Exact Sciences | 12 | $234 |
| Astellas Pharma US Inc | 10 | $224 |
| Novo Nordisk | 8 | $162 |
| Abbott | 9 | $161 |
| GSK | 8 | $156 |
| Bayer | 6 | $122 |
| Amgen(2 entities) | 7 | $121 |
| Merck | 7 | $114 |
| Endo Pharmaceuticals Inc. | 3 | $52 |
| Lundbeck LLC | 2 | $41 |
| VBI Vaccine (delaware) Inc. | 2 | $37 |
| Shield Therapeutics Inc | 2 | $36 |
| Tactile Systems Technology Inc | 1 | $33 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Pfizer | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$233
How this compares
$3,403 in reported general payments places this provider in the 85th percentile of 352 family medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $81,668 |
| JardianceEmpagliflozin | 54 | $69,124 |
| MounjaroTirzepatide | 48 | $58,118 |
| FarxigaDapagliflozin Propanediol | 31 | $43,308 |
| ProliaDenosumab | 23 | $38,697 |
| TradjentaLinagliptin | 27 | $37,054 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $22,806 |
| JanuviaSitagliptin Phosphate | 19 | $15,998 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $14,921 |
| MyrbetriqMirabegron | 14 | $14,052 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $12,844 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $10,468 |
| Rosuvastatin Calcium | 266 | $5,581 |
| Esomeprazole Magnesium | 29 | $5,345 |
| Lagevrio (Eua)Molnupiravir | 12 | $4,995 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $502 | $106,17881 claims |
| Novo NordiskOzempic | $162 | $81,66867 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $556 | $66,11451 claims |
| Lilly USA, LLCMounjaro | $467 | $58,11848 claims |
| AmgenProlia | $121 | $38,69723 claims |
| MerckJanuvia, Janumet, Lagevrio (Eua) | $114 | $33,83743 claims |
| GSKTrelegy Ellipta | $156 | $14,92120 claims |
| Astellas Pharma US IncMyrbetriq | $224 | $14,05214 claims |
| AbbVieSynthroid | $235 | $2,27436 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 352 family medicine providers in Delaware.
Other family medicine in Newark
- Michelle PapaNewark$23K
- Ian MyersNewark$17K
- Robert WinterNewark$12K
- Judy LimNewark$12K
- Huy leNewark$10K
- Arlen StoneNewark$10K
- Imelyn LaheyNewark$8K
- Angela Davis BrownNewark$8K
- Robert CallahanNewark$7K
- George NameyNewark$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.